3D Cell Culture Global Market - Forecast to 2028

Publishing Date : February, 2022
Report Code : HCBT0106
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Note: The report would be dispatched after confirmation of payment

3D cell culture is an artificial environment that allows biological cells to interact with the environment in a three-dimensional way, similar to cells "in vivo". Cells in a 3D cell culture model are subjected to stimuli and environmental conditions similar to those encountered by the cells of a living organism. The close replication of real-world conditions in 3D cell culture models has made them increasingly becoming popular in variety of applications like tissue engineering, drug discovery, toxicity testing, disease modelling, cancer research, stem cell research and others. The development of advanced scaffold based products (ready to use scaffold based plates, organ specific scaffolds etc), scaffold free products (portable bioreactor, organ on chip etc., and emerging high potential bioprinting technologies will further expands the 3D cell culture applications areas.

The 3D Cell culture global market is expected to grow at a mid teen CAGR from 2021 to 2028. The factors such as increasing funding towards the cell based research, increasing focus towards the application 3D cell culture models in in-vitro testing in drug discovery, toxicity testing due to advantages over 2D cell culture system are driving the 3D cell culture market. Whereas, growing focus towards application of 3D cell culture in the personalized and regenerative medicine and advancement is 3D cell culture technologies such as advanced bioreactors (integrated bioreactor and hand handled bioreactor), magnetic bioprinting or levitation, organ specific scaffolds and integration of AI technologies will provide immense growth opportunities for the 3D cell culture market. However, lack of skilled personnel, complications associated with establishment of 3D cell culture, ethical issues associated with 3D cell culture and stringent process control for handling 3D cell culture expected to hamper the market growth.

The market for 3D cell culture is segmented based on technology, products, end-user and geography. Based on the technology, the market is segmented into scaffold based platforms, scaffold free platforms and bioprinting. Among technologies, Scaffold based platforms is accounted for the highest revenue in 2021 and is expected to grow at a low teen CAGR from 2021 to 2028. Scaffold free platforms is expected to grow at a mid teen CAGR from 2021 to 2028 due to increasing adoption of scaffold free technologies in the development of 3D models such as spheroids and development of advanced scaffold free products such as integrated bioreactor, organ-on chip etc. The scaffold based platforms is further segmented into solid scaffolds, hydrogels and others. Among these, Solid Scaffolds segment is accounted for the highest revenue in 2021 and is expected to grow at a low teen CAGR from 2021 to 2028. Hydrogels is expected to grow at a mid teen CAGR from 2021 due to increasing development of advanced hydrogels. The scaffold free platforms is further segmented into hanging drop method, agitation based method, forced floating and microfluidics. Among these, Forced floating segment is accounted for the highest revenue in 2021 and is expected to grow at a mid teen CAGR from 2021 to 2028. Microfluidics is expected to grow at a high teen CAGR from 2021 to 2028.

Based on the products, the 3D cell culture market is classified into Cells& tissues, Media, Sera and Reagents, Microplates & Others, assay kits, scaffolds and Instruments. Among the products, media, sera and reagents accounted for the highest revenue in 2021 and are expected to grow at a mid teen CAGR from 2021 to 2028 due to an increase in demand for media and reagents in research, and drug discovery applications. Scaffolds segment are expected to grow at a mid teen CAGR from 2021 to 2028 due to development of innovative scaffolds by the companies. Scaffold segment is further sub segmented into natural scaffolds, synthetic scaffolds and hybrid composite. Among these, Natural scaffolds segment is accounted for the highest revenue in 2021 and are expected to grow at a mid teen CAGR from 2021 to 2028. Synthetic Scaffolds segment is expected to grow at a mid teen CAGR from 2021 to 2028.

Based on applications the 3D cell culture market is divided into basic research, toxicity and drug safety screening, tissue engineering, stem cell research, drug discovery, cancer research, and others. Among the applications, cancer research accounted for the highest revenue in 2021 and is expected to grow at a mid teen CAGR from 2021 to 2028. Stem cell research is expected to grow at a mid teen CAGR from 2021 to 2028.

Based on end users, 3D cell culture market is segmented into academic and research institution, biotechnology and pharmaceutical industry, and others. Among these Biotechnology & Pharmaceutical segment is accounted for the highest revenue in 2021 and is expected to grow at a low teen CAGR from 2021 to 2028 due to increasing focus towards the adoption of 3D cell culture in-vitro models in drug discovery and toxicity testing applications and increase in development of new drugs. Other end-users such as CRO’s is expected to grow at a mid teen CAGR from 2021 to 2028 due to increasing focus towards the adoption of 3D cell culture model in drug discovery by the CRO’s.

By geography, the3D cell culture global market is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, U.K. and Rest of Europe), Asia-Pacific (Japan, China, South Korea, and Rest of APAC) and the Rest of the world (Brazil, Rest of Latin America and the Middle East & Africa). North America accounted for the largest revenue in 2021 and is expected to grow at a low teen CAGR from 2021 to 2028. The factors increase in R&D expenditure, increasing government funding towards the cell based research, increasing drug discovery and development research and growing drug development pipelines, increasing interest towards the personalized medicine and regenerative medicine research and development of innovative 3D cell culture products by the companies for the application in research, drug discovery, and tissue engineering drivers the 3D cell culture market in the region.

Europe is expected to grow at a mid teen CAGR from 2021 to 2028.The factors such as increase in biotech R&D expenditure, presence of major biotech parks, entrepreneurship hubs with the ideal condition for biotech companies, venture capital providers, increasing number biotech companies, government funding for biotech innovative start-ups and cancer research stem cell research, growing drug discovery research by increasing investment in pharmaceutical sector to develop New Product Development (NPD) pipeline, development of advanced 3D cell culture products, entering of new companies with innovative 3D cell culture products and increase in private funding for the development of innovative 3D cell culture products are propelling  3D cell culture market in the region.

The 3D cell culture global market is competitive and all the players in this market are involved in adopting advanced technologies in 3D cell culture to expand their product portfolio and maintain their market shares. The key players in the 3D cell culture global market include Thermo Fisher Scientific (U.S.), Corning (U.S.), Lonza (Switzerland), Merck KGaA (Germany), Insphero (Switzerland), Reprocell (Japan), Greiner-Bio (Austria), Mimetas (Netherlands), Aspect Biosystem (Canada), BICO (Sweden) and 3D systems (U.S.).

The report provides an in-depth market analysis of the above-mentioned segments across the following region:

  • North America
  • U.S.
  • Rest of North America
  • Europe
  • Germany
  • U.K.
  • France
  • Rest of Europe
  • Asia-Pacific 
  • China
  • Japan
  • South Korea
  • Rest of APAC
  • Rest of the World (RoW)
  • Brazil
  • Rest of Latin America
  • Middle East and Others

TABLE OF CONTENTS

  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     SCOPE OF THE REPORT
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET BREAKDOWN AND DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.5     PRIMARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     MARKET SEGMENTATION
    • 3.4     FACTORS INFLUENCING MARKET
      • 3.4.1     DRIVERS AND OPPORTUNITIES
        • 3.4.1.1     USE OF 3D CELL CULTURE MODELS IN DRUG DISCOVERY AND DEVELOPMENT AS AN ALTERNATIVE TO ANIMAL TESTING
        • 3.4.1.2     INCREASING FUNDING TOWARDS THE CELL-BASED RESEARCH
        • 3.4.1.3     GROWING FOCUS TOWARDS THE DEVELOPMENT OF PERSONALIZED MEDICINE
        • 3.4.1.4     INCREASING TECHNOLOGICAL ADVANCEMENTS IN 3D CELL CULTURE
        • 3.4.1.5     INCREASING FOCUS ON REGENERATIVE MEDICINE
      • 3.4.2     RESTRAINTS AND THREATS
        • 3.4.2.1     LACK OF SKILLED PERSONNEL
        • 3.4.2.2     LACK OF STANDARDIZATION AND HIGH COST ASSOCIATED WITH 3D CELL CULTURE
        • 3.4.2.3     ETHICAL CHALLENGES ASSOCIATED WITH THE 3D CELL CULTURE
        • 3.4.2.4     STRINGENT PROCESS CONTROLS NEEDED FOR HANDLING 3D CELL CULTURE
    • 3.5     REGULATORY AFFAIRS
      • 3.5.1     UNITED STATES
      • 3.5.2     EUROPE
      • 3.5.3     INDIA
      • 3.5.4     JAPAN
    • 3.6     PORTER’S FIVE FORCE ANALYSIS
      • 3.6.1     THREAT OF NEW ENTRANTS
      • 3.6.2     THREAT OF SUBSTITUTES
      • 3.6.3     BARGAINING POWER OF SUPPLIERS
      • 3.6.4     BARGAINING POWER OF BUYERS
      • 3.6.5     COMPETITIVE RIVALRY
    • 3.7     SUPPLY CHAIN ANALYSIS
    • 3.8     FUNDING SCENARIO
    • 3.9     PATENT ANALYSIS
    • 3.1     DEAL ANALYSIS
    • 3.11     TECHNOLOGICAL ADVANCEMENTS
      • 3.11.1     INTRODUCTION
      • 3.11.2     ADVANCEMENT IN BIOREACTOR SYSTEM
      • 3.11.3     ARTIFICIAL INTELLIGENCE IN 3D CELL CULTURE
      • 3.11.4     MAGNETIC LEVITATION OR MAGNETIC BIOPRINTING
      • 3.11.5     PANDA SYSTEM
      • 3.11.6     DEVELOPMENT OF PATIENT DERIVED ORGANIODS
      • 3.11.7     DEVELOPMENT OF ORGAN SPECIFIC SCAFFOLDS
      • 3.11.8     DEVELOPMENT OF 3D CELL CULTURE WORKSTATIONS
      • 3.11.9     ULTRASONIC STANDING WAVE METHOD
    • 3.12     IMPACT OF COVID-19 ON 3D CELL CULTURE MARKET
    • 3.13     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
  • 4     3D CELL CULTURE GLOBAL MARKET, BASED ON TECHNOLOGY
    • 4.1     INTRODUCTION
    • 4.2     SCAFFOLD BASED PLATFORMS
      • 4.2.1     SOLID SCAFFOLDS
      • 4.2.2     HYDROGELS
      • 4.2.3     OTHERS
    • 4.3     SCAFFOLD FREE PLATFORMS
      • 4.3.1     HANGING DROP METHOD
      • 4.3.2     FORCED FLOATING
      • 4.3.3     AGITATION BASED METHOD
      • 4.3.4     MICROFLUIDICS
    • 4.4     BIOPRINTING
  • 5     3D CELL CULTURE GLOBAL MARKET, BY PRODUCTS
    • 5.1     INTRODUCTION
    • 5.2     CELLS AND TISSUES
    • 5.3     MEDIA, SERA AND REAGENTS
    • 5.4     MICROPLATES AND OTHERS
    • 5.5     ASSAY KITS
    • 5.6     SCAFFOLDS
      • 5.6.1     NATURAL SCAFFOLDS
      • 5.6.2     SYNTHETIC SCAFFOLDS
      • 5.6.3     HYBRID COMPOSITE
    • 5.7     INSTRUMENTS
  • 6     3D CELL CULTURE GLOBAL MARKET, BY APPLICATION
    • 6.1     INTRODUCTION
    • 6.2     BASIC RESEARCH
    • 6.3     TOXICITY AND DRUG SAFETY SCREENING
    • 6.4     TISSUE ENGINEERING
    • 6.5     STEM CELL RESEARCH
    • 6.6     DRUG DISCOVERY
    • 6.7     CANCER RESEARCH
    • 6.8     OTHERS
  • 7     3D CELL CULTURE GLOBAL MARKET, BY END-USERS
    • 7.1     INTRODUCTION
    • 7.2     ACADEMIC AND RESEARCH INSTITUTES
    • 7.3     BIOTECHNOLOGY AND PHARMACEUTICAL INDUSTRIES
    • 7.4     OTHERS
  • 8     REGIONAL ANALYSIS
    • 8.1     INTRODUCTION
    • 8.2     NORTH AMERICA
      • 8.2.1     U.S.
      • 8.2.2     REST OF NORTH AMERICA
    • 8.3     EUROPE
      • 8.3.1     GERMANY
      • 8.3.2     U.K.
      • 8.3.3     FRANCE
      • 8.3.4     REST OF EUROPE
    • 8.4     ASIA-PACIFIC
      • 8.4.1     CHINA
      • 8.4.2     JAPAN
      • 8.4.3     SOUTH KOREA
      • 8.4.4     REST OF APAC
    • 8.5     REST OF THE WORLD
      • 8.5.1     BRAZIL
      • 8.5.2     REST OF LATIN AMERICA
      • 8.5.3     MIDDLE EAST AND OTHERS
  • 9     COMPETITIVE LANDSCAPE
    • 9.1     INTRODUCTION
    • 9.2     COLLABORATIONS & AGREEMENT
    • 9.3     NEW PRODUCT LAUNCH
    • 9.4     ACQUISITIONS
    • 9.5     OTHERS
  • 10     MAJOR COMPANIES
    • 10.1     3D SYSTEMS
      • 10.1.1     OVERVIEW
      • 10.1.2     FINANCIALS
      • 10.1.3     PRODUCT PORTFOLIO
      • 10.1.4     KEY DEVELOPMENTS
      • 10.1.5     BUSINESS STRATEGY
      • 10.1.6     SWOT ANALYSIS
    • 10.2     ASPECT BIOSYSTEMS
      • 10.2.1     OVERVIEW
      • 10.2.2     FINANCIALS
      • 10.2.3     PRODUCT PORTFOLIO
      • 10.2.4     KEY DEVELOPMENTS
      • 10.2.5     BUSINESS STRATEGY
      • 10.2.6     SWOT ANALYSIS
    • 10.3     BICO(CELLINK)
      • 10.3.1     OVERVIEW
      • 10.3.2     FINANCIALS
      • 10.3.3     PRODUCT PORTFOLIO
      • 10.3.4     KEY DEVELOPMENTS
      • 10.3.5     BUSINESS STRATEGY
      • 10.3.6     SWOT ANALYSIS
    • 10.4     CORNING INCORPORATED
      • 10.4.1     OVERVIEW
      • 10.4.2     FINANCIALS
      • 10.4.3     PRODUCT PORTFOLIO
      • 10.4.4     KEY DEVELOPMENTS
      • 10.4.5     BUSINESS STRATEGY
      • 10.4.6     SWOT ANALYSIS
    • 10.5     GREINER AG
      • 10.5.1     OVERVIEW
      • 10.5.2     FINANCIALS
      • 10.5.3     PRODUCT PORTFOLIO
      • 10.5.4     KEY DEVELOPMENTS
      • 10.5.5     BUSINESS STRATEGY
      • 10.5.6     SWOT ANALYSIS
    • 10.6     INSPHERO AG
      • 10.6.1     OVERVIEW
      • 10.6.2     FINANCIALS
      • 10.6.3     PRODUCT PORTFOLIO
      • 10.6.4     KEY DEVELOPMENTS
      • 10.6.5     BUISNESS STRATERGY
      • 10.6.6     SWOT ANALYSIS
    • 10.7     LONZA GROUP
      • 10.7.1     OVERVIEW
      • 10.7.2     FINANCIALS
      • 10.7.3     PRODUCT PORTFOLIO
      • 10.7.4     KEY DEVELOPMENTS
      • 10.7.5     BUSINESS STRATEGY
      • 10.7.6     SWOT ANALYSIS
    • 10.8     MERCK KGAA
      • 10.8.1     OVERVIEW
      • 10.8.2     FINANCIALS
      • 10.8.3     PRODUCT PORTFOLIO
      • 10.8.4     KEY DEVELOPMENTS
      • 10.8.5     BUSINESS STRATEGY
      • 10.8.6     SWOT ANALYSIS
    • 10.9     MIMETAS
      • 10.9.1     OVERVIEW
      • 10.9.2     FINANCIALS
      • 10.9.3     PRODUCT PORTFOLIO
      • 10.9.4     KEY DEVELOPMENTS
      • 10.9.5     BUSINESS STRATEGY
      • 10.9.6     SWOT ANALYSIS
    • 10.1     REPROCELL, INC
      • 10.10.1     OVERVIEW
      • 10.10.2     FINANCIALS
      • 10.10.3     PRODUCT PORTFOLIO
      • 10.10.4     KEY DEVELOPMENTS
      • 10.10.5     BUSINESS STRATEGY
      • 10.10.6     SWOT ANALYSIS
    • 10.11     THERMO FISHER SCIENTIFIC, INC
      • 10.11.1     OVERVIEW
      • 10.11.2     FINANCIALS
      • 10.11.3     PRODUCT PORTFOLIO
      • 10.11.4     KEY DEVELOPMENTS
      • 10.11.5     BUSINESS STRATEGY
      • 10.11.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     3D CELL CULTURE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 2     NEW PRODUCT LAUNCH (2020-2021)
      • TABLE 3     COLLABORATION, PARTENRSHIP AND AGREEMENT (2020-2021)
      • TABLE 4     3D CELL CULTURE GLOBAL MARKET REVENUE, BASED ON TECHNOLOGY, (2020-2028) ($MN)
      • TABLE 5     SCAFFOLD BASED PLATFORMS GLOBAL MARKET REVENUE, BASED ON TYPE, (2020-2028) ($MN)
      • TABLE 6     SCAFFOLD BASED PLATFORMS MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 7     SOLID SCAFFOLDS MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 8     HYDROGELS MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 9     OTHERS MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 10     SCAFFOLD FREE PLATFORMS GLOBAL MARKET REVENUE, BASED ON TYPE, (2020-2028) ($MN)
      • TABLE 11     SCAFFOLD FREE PLATFORMS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 12     HANGING DROP METHOD GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 13     FORCED FLOATING GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 14     AGITATION BASED METHODS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 15     MICROFLUIDICS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 16     BIOPRINTING GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 17     3D CELL CULTURE GLOBAL MARKET REVENUE, BASED ON PRODUCTS, (2020-2028) ($MN)
      • TABLE 18     CELLS & TISSUES GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 19     MEDIA, SERA & REAGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 20     MICROPLATES & OTHERS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 21     ASSAY KITS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 22     SCAFFOLDS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 23     SCAFFOLDS GLOBAL MARKET REVENUE, BASED ON TYPE, (2020-2028) ($MN)
      • TABLE 24     NATURAL SCAFFOLDS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 25     SYNTHETIC SCAFFOLDS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 26     HYBRID COMPOSITE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 27     INSTRUMENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 28     3D CELL CULTURE GLOBAL MARKET REVENUE, BASED ON APPLICATION, (2020-2028) ($MN)
      • TABLE 29     BASIC REASEARCH GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 30     TOXICITY AND DRUG SAFETY SCREENING GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 31     TISSUE ENGINEERING GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 32     STEM CELL RESEARCH GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 33     DRUG DISCOVERY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 34     CANCER RESEARCH GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 35     OTHERS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 36     3D CELL CULTURE GLOBAL MARKET REVENUE, BASED ON END-USERS, (2020-2028) ($MN)
      • TABLE 37     ACADEMIC AND RESEARCH INSTITUTES GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 38     BIOTECHNOLOGY AND PHARMACEUTICAL INDUSTRIES GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 39     OTHERS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 40     3D CELL CULTURE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 41     NORTH AMERICA 3D CELL CULTURE MARKET REVENUE, BASED ON TECHNOLOGY (2020-2028) ($MN)
      • TABLE 42     NORTH AMERICA SCAFFOLD BASED PLATFORMS MARKET REVENUE, BASED ON TYPE (2020-2028) ($MN)
      • TABLE 43     NORTH AMERICA SCAFFOLD FREE PLATFORMS MARKET REVENUE, BASED ON TYPE (2020-2028) ($MN)
      • TABLE 44     198 NORTH AMERICA 3D CELL CULTURE MARKET REVENUE, BASED ON PRODUCTS, (2020-2028) ($MN)
      • TABLE 45     NORTH AMERICA SCAFFOLDS MARKET REVENUE, BY TYPE, (2020-2028) ($MN)
      • TABLE 46     NORTH AMERICA 3D CELL CULTURE MARKET REVENUE, BASED ON APPLICATION, (2020-2028) ($MN)
      • TABLE 47     NORTH AMERICA 3D CELL CULTURE MARKET REVENUE, BASED ON END-USER, (2020-2028) ($MN)
      • TABLE 48     NORTH AMERICA 3D CELL CULTURE MARKET REVENUE, BASED ON COUNTRY (2020-2028) ($MN)
      • TABLE 49     EUROPE 3D CELL CULTURE MARKET REVENUE, BASED ON TECHNOLOGY (2020-2028) ($MN)
      • TABLE 50     EUROPE SCAFFOLD BASED PLATFORMS MARKET REVENUE, BASED ON TYPE (2020-2028) ($MN)
      • TABLE 51     EUROPE SCAFFOLD FREE PLATFORMS MARKET REVENUE, BASED ON TYPE (2020-2028) ($MN)
      • TABLE 52     EUROPE 3D CELL CULTURE MARKET REVENUE, BASED ON PRODUCTS, (2020-2028) ($MN)
      • TABLE 53     EUROPE SCAFFOLDS MARKET REVENUE, BASED ON TYPE, (2020-2028) ($MN)
      • TABLE 54     EUROPE 3D CELL CULTURE MARKET REVENUE, BASED ON APPLICATION, (2020-2028) ($MN)
      • TABLE 55     EUROPE 3D CELL CULTURE MARKET REVENUE, BASED ON END-USER, (2020-2028) ($MN)
      • TABLE 56     EUROPE 3D CELL CULTURE MARKET REVENUE, BASED ON COUNTRY (2020-2028) ($MN)
      • TABLE 57     APAC 3D CELL CULTURE MARKET REVENUE, BASED ON TECHNOLOGY (2020-2028) ($MN)
      • TABLE 58     APAC SCAFFOLD BASED PLATFORMS MARKET REVENUE, BASED ON TYPE (2020-2028) ($MN)
      • TABLE 59     APAC SCAFFOLD FREE PLATFORMS MARKET REVENUE, BASED ON TYPE (2020-2028) ($MN)
      • TABLE 60     APAC 3D CELL CULTURE MARKET REVENUE, BASED ON PRODUCTS, (2020-2028) ($MN)
      • TABLE 61     APAC SCAFFOLDS MARKET REVENUE, BY TYPE, (2020-2028) ($MN)
      • TABLE 62     APAC 3D CELL CULTURE MARKET REVENUE, BASED ON APPLICATION, (2020-2028) ($MN)
      • TABLE 63     APAC 3D CELL CULTURE MARKET REVENUE, BASED ON END-USER, (2020-2028) ($MN)
      • TABLE 64     APAC 3D CELL CULTURE MARKET REVENUE, BASED ON COUNTRY (2020-2028) ($MN)
      • TABLE 65     ROW 3D CELL CULTURE MARKET REVENUE, BASED ON TECHNOLOGY (2020-2028) ($MN)
      • TABLE 66     ROW SCAFFOLD BASED PLATFORMS MARKET REVENUE, BASED ON TYPE (2020-2028) ($MN)
      • TABLE 67     ROW SCAFFOLD FREE PLATFORMS MARKET REVENUE, BASED ON TYPE (2020-2028) ($MN)
      • TABLE 68     ROW 3D CELL CULTURE MARKET REVENUE, BASED ON PRODUCTS, (2020-2028) ($MN)
      • TABLE 69     ROW SCAFFOLDS MARKET REVENUE, BASED ON TYPE, (2020-2028) ($MN)
      • TABLE 70     ROW 3D CELL CULTURE MARKET REVENUE, BASED ON APPLICATION, (2020-2028) ($MN)
      • TABLE 71     ROW 3D CELL CULTURE MARKET REVENUE, BASED ON END-USER, (2020-2028) ($MN)
      • TABLE 72     ROW 3D CELL CULTURE MARKET REVENUE, BASED ON COUNTRY (2020-2028) ($MN)
      • TABLE 73     COLLABORATIONS & PARTNERSHIPS (2020 – 2021)
      • TABLE 74     NEW PRODUCT LAUNCH (2020 – 2021)
      • TABLE 75     ACQUISITION (2020 – 2021)
      • TABLE 76     3D SYSTEMS: TOTAL REVENUE AND R&D EXPENSES, (2020-2021) (Q3) ($MN)
      • TABLE 77     3D SYSTEMS: TOTAL REVENUE, BY SEGMENTS, (2020-2021) (Q3) ($MN)
      • TABLE 78     3D SYSTEMS : TOTAL REVENUE, BY GEOGRAPHY, (2020-2021) (Q3) ($MN)
      • TABLE 79     BICO: TOTAL REVENUE AND R&D EXPENSES, (2020-2021) (Q3) ($MN)
      • TABLE 80     BICO: TOTAL REVENUE, BY SEGMENTS, (2020-2021) (Q3) ($MN)
      • TABLE 81     BICO: TOTAL REVENUE, BY GEOGRAPHY, (2020-2021) (Q3) ($MN)
      • TABLE 82     CORNING INCORPORATED: TOTAL REVENUE AND R&D EXPENSES, (2020-2021) (Q3) ($MN)
      • TABLE 83     CORNING INCORPORATED: TOTAL REVENUE, BY SEGMENTS, (2020-2021) (Q3) ($MN)
      • TABLE 84     CORNING INCORPORATED: TOTAL REVENUE, BY GEOGRAPHY, (2020-2021) (Q3) ($MN)
      • TABLE 85     GREINER AG: TOTAL REVENUE AND R&D EXPENSES (2018-2020) ($MN)
      • TABLE 86     GREINER AG: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
      • TABLE 87     GREINER AG: TOTAL REVENUE, BY GEOGRAPHY (2018-2020) ($MN)
      • TABLE 88     LONZA GROUP: TOTAL REVENUE AND R&D EXPENSES (2020-2021) (Q2) ($MN)
      • TABLE 89     LONZA GROUP: TOTAL REVENUE, BY SEGMENT, (2020-2021)(Q2) ($MN)
      • TABLE 90     MERCK KGAA: TOTAL REVENUE AND R&D EXPENSES, (2020-2021) (Q3) ($MN)
      • TABLE 91     MERCK KGAA: TOTAL REVENUE, BY SEGMENTS, (2020-2021) (Q3) ($MN)
      • TABLE 92     MERCK KGAA: TOTAL REVENUE, BY SUB-SEGMENTS, (2020-2021) (Q3) ($MN)
      • TABLE 93     MERCK KGAA: TOTAL REVENUE, BY GEOGRAPHY, (2020-2021)(Q3) ($MN)
      • TABLE 94     THERMO FISHER SCIENTIFIC, INC: TOTAL REVENUE AND R&D EXPENSES (2020-2021)(Q3) ($MN)
      • TABLE 95     THERMO FISHER SCIENTIFIC, INC: TOTAL REVENUE, BY SEGMENT, (2020-2021) (Q3)($MN)
      • TABLE 96     THERMO FISHER SCIENTIFIC, INC: TOTAL REVENUE, BY GEOGRAPHY (2020-2021) (Q3)($MN)

      LIST OF FIGURES

      • FIGURE 1     3D CELL CULTURE GLOBAL MARKET SHARE AND REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: 3D CELL CULTURE GLOBAL MARKET
      • FIGURE 3     3D CELL CULTURE GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     3D CELL CULTURE GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     3D CELL CULTURE: MARKET BREAKDOWN & DATA TRIANGULATION
      • FIGURE 6     3D CELL CULTURE GLOBAL MARKET: MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     3D CELL CULTURE GLOBAL MARKET: PORTER’S ANALYSIS
      • FIGURE 9     3D CELL CULTURE GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
      • FIGURE 10     3D CELL CULTURE MARKET: PATENT FILING BY MAJOR PLAYERS (2017-2021)
      • FIGURE 11     3D CELL CULTURE GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, (2021)
      • FIGURE 12     3D CELL CULTURE GLOBAL MARKET SHARE, BASED ON TECHNOLOGY, (2021 VS 2028) (%)
      • FIGURE 13     SCAFFOLD BASED PLATFORMS GLOBAL MARKET SHARE, BASED ON TYPE, (2021 VS 2028) (%)
      • FIGURE 14     SCAFFOLD FREE PLATFORMS GLOBAL MARKET SHARE, BASED ON TYPE, (2021 VS 2028) (%)
      • FIGURE 15     3D CELL CULTURE GLOBAL MARKET SHARE, BASED ON PRODUCTS, (2021 V/S 2028) (%)
      • FIGURE 16     SCAFFOLDS GLOBAL MARKET SHARE, BASED ON TYPE, (2021 V/S 2028) (%)
      • FIGURE 17     3D CELL CULTURE GLOBAL MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2028) (%)
      • FIGURE 18     DRUG DISCOVERY GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 19     3D CELL CULTURE GLOBAL MARKET SHARE, BASED ON END-USERS, (2021 V/S 2028) (%)
      • FIGURE 20     3D CELL CULTURE GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN), CAGR (%)
      • FIGURE 21     3D CELL CULTURE GLOBAL MARKET REVENUE, BY GEOGRAPHY (2021) ($ MN)
      • FIGURE 22     NORTH AMERICA 3D CELL CULTURE MARKET SHARE, BASED ON TECHNOLOGY (2021 VS 2028) (%)
      • FIGURE 23     NORTH AMERICA SCAFFOLD BASED PLATFORMS MARKET SHARE, BASED ON TYPE (2021 VS 2028) (%)
      • FIGURE 24     NORTH AMERICA SCAFFOLD FREE PLATFORMS MARKET SHARE, BASED ON TYPE (2021 VS 2028) (%)
      • FIGURE 25     NORTH AMERICA 3D CELL CULTURE MARKET SHARE, BY PRODUCTS (2021 VS 2028) (%)
      • FIGURE 26     NORTH AMERICA SCAFFOLDS MARKET SHARE, BASED ON TYPE (2021 VS 2028) ($MN)
      • FIGURE 27     NORTH AMERICA 3D CELL CULTURE MARKET SHARE, BASED ON APPLICATION (2021 VS 2028) (%)
      • FIGURE 28     NORTH AMERICA 3D CELL CULTURE MARKET SHARE, BASED ON END-USER (2021 VS 2028) (%)
      • FIGURE 29     NORTH AMERICA 3D CELL CULTURE MARKET SHARE, BASED ON COUNTRY (2021 V/S 2028) (%)
      • FIGURE 30     U.S. 3D CELL CULTURE MARKET REVENUE, BASED ON TECHNOLOGY & PRODUCTS (2021 VS 2028)($MN)
      • FIGURE 31     U.S. 3D CELL CULTURE MARKET REVENUE, BASED ON APPLICATIONS & END-USER (2021 VS 2028)($MN)
      • FIGURE 32     REST OF NORTH AMERICA 3D CELL CULTURE MARKET REVENUE, BASED ON TECHNOLOGY & PRODUCTS (2021 VS 2028) ($MN)
      • FIGURE 33     REST OF NORTH AMERICA 3D CELL CULTURE MARKET REVENUE, BASED ON APPLICATIONS & END-USER (2021 VS 2028) ($MN)
      • FIGURE 34     EUROPE 3D CELL CULTURE MARKET SHARE, BASED ON TECHNOLOGY (2021 VS 2028) (%)
      • FIGURE 35     EUROPE SCAFFOLD BASED PLATFORMS MARKET SHARE, BASED ON TYPE (2021 VS 2028) (%)
      • FIGURE 36     EUROPE SCAFFOLD FREE PLATFORMS MARKET SHARE, BASED ON TYPE (2021 VS 2028) (%)
      • FIGURE 37     EUROPE 3D CELL CULTURE MARKET SHARE, BASED ON PRODUCTS (2021 VS 2028) (%)
      • FIGURE 38     EUROPE SCAFFOLDS MARKET SHARE, BASED ON TYPE (2021 VS 2028) (%)
      • FIGURE 39     EUROPE 3D CELL CULTURE MARKET SHARE, BASED ON APPLICATION (2021 VS 2028) (%)
      • FIGURE 40     EUROPE 3D CELL CULTURE MARKET SHARE, BASED ON END-USERS (2021 VS 2028) (%)
      • FIGURE 41     EUROPE 3D CELL CULTURE MARKET SHARE, BASED ON COUNTRY (2021 V/S 2028) (%)
      • FIGURE 42     GERMANY 3D CELL CULTURE MARKET REVENUE, BASED ON TECHNOLOGY & PRODUCTS (2021 VS 2028) ($MN)
      • FIGURE 43     GERMANY 3D CELL CULTURE MARKET REVENUE, BASED ON APPLICATIONS & END-USER (2021 VS 2028) ($MN)
      • FIGURE 44     U.K. 3D CELL CULTURE MARKET REVENUE, BASED ON TECHNOLOGY & PRODUCTS (2021 VS 2028) ($MN)
      • FIGURE 45     U.K. 3D CELL CULTURE MARKET REVENUE, BASED ON APPLICATIONS & END-USER (2021 VS 2028) ($MN)
      • FIGURE 46     FRANCE 3D CELL CULTURE MARKET REVENUE, BASED ON TECHNOLOGY & PRODUCTS (2021 VS 2028) ($MN)
      • FIGURE 47     FRANCE 3D CELL CULTURE MARKET REVENUE, BASED ON APPLICATIONS & END-USER (2021 VS 2028) ($MN)
      • FIGURE 48     REST OF EUROPE 3D CELL CULTURE MARKET REVENUE, BASED ON TECHNOLOGY & PRODUCTS (2021 VS 2028) ($MN)
      • FIGURE 49     REST OF EUROPE 3D CELL CULTURE MARKET REVENUE, BASED ON APPLICATIONS & END-USER (2021 VS 2028) ($MN)
      • FIGURE 50     APAC 3D CELL CULTURE MARKET SHARE, BASED ON TECHNOLOGY (2021 VS 2028) (%)
      • FIGURE 51     APAC SCAFFOLD BASED PLATFORMS MARKET SHARE, BASED ON TYPE (2021 VS 2028) (%)
      • FIGURE 52     APAC SCAFFOLD FREE PLATFORMS MARKET SHARE, BASED ON TYPE (2021 VS 2028) (%)
      • FIGURE 53     APAC 3D CELL CULTURE MARKET SHARE, BASED ON PRODUCTS (2021 VS 2028) (%)
      • FIGURE 54     APAC SCAFFOLDS MARKET SHARE, BASED ON TYPE (2021 VS 2028) (%)
      • FIGURE 55     APAC 3D CELL CULTURE MARKET SHARE, BASED ON APPLICATION (2021 VS 2028) (%)
      • FIGURE 56     APAC 3D CELL CULTURE MARKET SHARE, BASED ON END-USERS (2021 VS 2028) ($MN)
      • FIGURE 57     APAC 3D CELL CULTURE MARKET SHARE, BASED ON COUNTRY (2021 V/S 2028) (%)
      • FIGURE 58     CHINA 3D CELL CULTURE MARKET REVENUE, BASED ON TECHNOLOGY & PRODUCTS (2021 VS 2028) ($MN)
      • FIGURE 59     CHINA 3D CELL CULTURE MARKET REVENUE, BASED ON APPLICATIONS & END-USER (2021 VS 2028) ($MN)
      • FIGURE 60     JAPAN 3D CELL CULTURE MARKET REVENUE, BASED ON TECHNOLOGY & PRODUCTS (2021 VS 2028) ($MN)
      • FIGURE 61     JAPAN 3D CELL CULTURE MARKET REVENUE, BASED ON APPLICATIONS & END-USER (2021 VS 2028) ($MN)
      • FIGURE 62     SOUTH KOREA 3D CELL CULTURE MARKET REVENUE, BASED TECHNOLOGY & BY PRODUCTS (2021 VS 2028) ($MN)
      • FIGURE 63     SOUTH KOREA 3D CELL CULTURE MARKET REVENUE, BASED ON APPLICATION AND END-USER (2021 VS 2028) ($MN)
      • FIGURE 64     REST OF APAC COUNTRIES 3D CELL CULTURE MARKET REVENUE, BASED ON TECHNOLOGY & PRODUCTS, (2021 VS 2028) ($MN)
      • FIGURE 65     REST OF APAC 3D CELL CULTURE MARKET REVENUE, BASED ON APPLICATIONS & END-USER (2021 VS 2028) ($MN)
      • FIGURE 66     ROW 3D CELL CULTURE MARKET SHARE, BASED ON TECHNOLOGY (2021 VS 2028) (%)
      • FIGURE 67     ROW SCAFFOLD BASED PLATFORMS MARKET SHARE, BASED ON TYPE (2021 VS 2028) (%)
      • FIGURE 68     ROW SCAFFOLD FREE BASED PLATFORMS MARKET SHARE, BASED ON TYPE (2021 VS 2028) (%)
      • FIGURE 69     ROW 3D CELL CULTURE MARKET SHARE, BY PRODUCTS (2021 VS 2028) (%)
      • FIGURE 70     ROW SCAFFOLDS MARKET SHARE, BY TYPE (2021 VS 2028) (%)
      • FIGURE 71     ROW 3D CELL CULTURE MARKET SHARE, BASED ON APPLICATION (2021 VS 2028) (%)
      • FIGURE 72     ROW 3D CELL CULTURE MARKET SHARE, BASED ON END-USER (2021 VS 2028) (%)
      • FIGURE 73     ROW 3D CELL CULTURE MARKET SHARE, BASED ON COUNTRY (2021 V/S 2028) (%)
      • FIGURE 74     BRAZIL 3D CELL CULTURE MARKET REVENUE, BASED ON TECHNOLOGY & PRODUCTS (2021 VS 2028) ($MN)
      • FIGURE 75     BRAZIL 3D CELL CULTURE MARKET REVENUE, BASED ON APPLICATIONS & ENDUSER (2021 VS 2028) ($MN)
      • FIGURE 76     REST OF LATIN AMERICA 3D CELL CULTURE MARKET REVENUE, BASED ON TECHNOLOGY & PRODUCTS (2021 VS 2028) ($MN)
      • FIGURE 77     REST OF LATIN AMERICA 3D CELL CULTURE MARKET REVENUE, BASED ON APPLICATIONS & ENDUSER (2021 VS 2028) ($MN)
      • FIGURE 78     MIDDLE EAST AND OTHERS 3D CELL CULTURE MARKET REVENUE, BASED ON TECHNOLOGY & PRODUCTS (2021 VS 2028) ($MN)
      • FIGURE 79     MIDDLE EAST AND OTHERS 3D CELL CULTURE MARKET REVENUE, BASED ON APPLICATIONS & ENDUSER (2021 VS 2028) ($MN)
      • FIGURE 80     KEY GROWTH STRATEGIES, (2020 – 2021)
      • FIGURE 81     SWOT: 3D SYSTEMS
      • FIGURE 82     SWOT: ASPECT BIOSYSTEMS
      • FIGURE 83     SWOT: BICO
      • FIGURE 84     SWOT: CORNING INCORPORATED
      • FIGURE 85     SWOT: GREINER AG
      • FIGURE 86     SWOT: INSPHERO AG
      • FIGURE 87     SWOT: LONZA GROUP
      • FIGURE 88     SWOT: MERCK KGAA
      • FIGURE 89     SWOT: MIMETAS
      • FIGURE 90     SWOT: REPROCELL INC.
      • FIGURE 91     SWOT: THERMO FISHER SCIENTIFIC, INC

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     300 Microns GmbH
      • 2     3D BioFibR Inc
      • 3     3D Biotek, LLC
      • 4     3D systems
      • 5     3C-Labs
      • 6     Abcam (BioVision, Inc.)
      • 7     ABLE Corporation
      • 8     Advanced Solutions Life Sciences, LLC
      • 9     AIM Biotech PTE Ltd.
      • 10     amsbio LLC
      • 11     Aspect biosystems
      • 12     Avanticell Science
      • 13     Bellco Glass, Inc
      • 14     BICO (Cellink)
      • 15     BioIVT(Asterand Bioscience)
      • 16     Biolamina AB
      • 17     Bellbrook Labs
      • 18     Bio-Techne Corporation
      • 19     BISS TGT
      • 20     Black Drop Biodrucker GmbH
      • 21     Brinter
      • 22     BRTI Life Sciences
      • 23     Cell Applications, Inc.
      • 24     Cell bio labs
      • 25     Cellaria Inc
      • 26     CellecBiotek AG
      • 27     Cellendes GmbH
      • 28     Cellevate AB
      • 29     CELLnTEC Advanced Cell Systems AG
      • 30     Celprogen
      • 31     CelVivo IVS
      • 32     CollPlant Biotechnologies
      • 33     Corning Incorporated
      • 34     Cyfuse Biomedical KK
      • 35     CN Bio Innovations
      • 36     EBERS Medical Technology SL
      • 37     Ectica Technologies AG
      • 38     Electrospinning Company
      • 39     eNUVIO Inc
      • 40     ESI Bio
      • 41     faCellitate
      • 42     FiberCell Systems Inc
      • 43     Fluicell
      • 44     Genlantis (Gene Therapy Systems, Inc.)
      • 45     GeSiM GmbH
      • 46     Gradientech AB
      • 47     Greiner AG(Greiner Bio-One GmbH)
      • 48     Guangzhou JET Bio-Filtration Co., Ltd.
      • 49     HCS Pharma
      • 50     ibidi GmbH
      • 51     Insphero
      • 52     Inventia Life Science
      • 53     Jellagen
      • 54     JSR Corporation (Organogenix Inc.)
      • 55     Kugelmeiers Ag
      • 56     Lena Biosciences, Inc.
      • 57     Lonza Group
      • 58     Manchester BIOGEL
      • 59     Merck KGaA
      • 60     Microtissues, Inc.
      • 61     Mimetas B.V.
      • 62     Nanofiber Solutions
      • 63     Neuromics Inc
      • 64     Nobel Biocare(Matricel GmbH)
      • 65     Omni Life science
      • 66     Organovo Holdings, Inc
      • 67     PepGel LLC
      • 68     PerkinElmer
      • 69     PHC Corporation
      • 70     Pishon Biomedical
      • 71     Prodizen
      • 72     Promega Corporation
      • 73     PromoCell GmbH
      • 74     RealBio Holdings LLC
      • 75     Regemat 3D S.L
      • 76     Regenhu
      • 77     Regenovo
      • 78     Reprocell (Reinnervate Ltd)
      • 79     Rigenerand
      • 80     Rokit
      • 81     Sartorius Stedim Biotech
      • 82     STEMCELL Technologies Inc.
      • 83     Synthecon, Inc
      • 84     SUN bioscience
      • 85     SynVivo LLC
      • 86     Takara Bio Inc (Clontech)
      • 87     The Well Bioscience Inc.
      • 88     Thermo Fisher Scientific
      • 89     UPM Biomedicals
      • 90     UpNano GmbH
      • 91     Xpect INX